The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2, as well as other coronaviruses.
UMFK announces annual student awards and scholarships Contributed • May 19, 2021 The University of Maine at Fort Kent has announced its annual student awards and scholarships recently presented to both undergraduate students and those who graduated this spring.
FORT KENT, Maine – The University of Maine at Fort Kent has announced its annual student awards and scholarships recently presented to both undergraduate students and those who graduated this spring. These awards and scholarships are presented to deserving students for their contributions to campus and their academic achievements.
John L. Martin Environmental Scholarship Award was presented to Jacob Paris (Fort Kent). Shane Tweedie (Winthrop) and Andrew Kooken (Hampstead, New Hampshire) were presented the Thomas S. Pinkham Memorial Scholarship.
UMFK announces annual student awards and scholarships thecounty.me - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thecounty.me Daily Mail and Mail on Sunday newspapers.
UMFK students earn awards, scholarships
Share
The University of Maine at Fort Kent recently presented its annual student awards and scholarships to both undergraduate students and those who graduated this spring.
These awards and scholarships are presented to deserving students for their contributions to the campus and their academic achievements.
Jacob Paris of Fort Kent was presented the John L. Martin Environmental Scholarship Award. The Thomas S. Pinkham Memorial Scholarship was awarded to Shane Tweedie of Winthrop and Andrew Kooken on Hampstead, New Hampshire.
Luse Lumas of Tracy, California, was honored with the Student Senate Outstanding Senior. Luke Mason of Bethel was presented the UMFK Alumni Association Outstanding Senior Award.
Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma First disclosure of results from CheckMate -648 demonstrate Opdivo plus Yervoy and Opdivo plus chemotherapy’s potential to address unmet needs in …
First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma